Surprisingly, we found that the level of intratumor IFN-γ was elevated after mcr84 treatment (Figure 4A), highlighting that the decrease of PD-L1 on tumor-associated myeloid cells was not due to a reduction of IFN-γ in the tumor microenvironment. The gene discussed is IFNG; the disease is neoplasm.